Evidence map›Paper›PMID 31540495›Full record

ArticleCancers2019

Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.

Mi-Ae Kang, Jongsung Lee, Sang Hoon Ha, Chang Min Lee, Kyoung Min Kim, Kyu Yun Jang, See-Hyoung Park

Abstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mi-Ae KangDepartment of Biological Science, Gachon University, Seongnam 13120, Korea. makang53@hanmail.net.
Jongsung LeeDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Korea. bioneer@skku.edu.ORCID 0000-0002-5073-2619
Sang Hoon HaDivision of Biotechnology, Chonbuk National University, Iksan 54596, Korea. hasangpos@gmail.com.
Chang Min LeeDepartment of Bio and Chemical Engineering, Hongik University, Sejong 30016, Korea. yycc456@naver.com.
Kyoung Min KimDepartment of Pathology, Chonbuk National University Medical School, Chonbuk National University, Jeonju 54896, Korea. kmkim@jbnu.ac.kr.
Kyu Yun JangDepartment of Pathology, Chonbuk National University Medical School, Chonbuk National University, Jeonju 54896, Korea. kyjang@chonbuk.ac.kr.ORCID 0000-0002-5276-4446
See-Hyoung ParkDepartment of Bio and Chemical Engineering, Hongik University, Sejong 30016, Korea. shpark74@hongik.ac.kr.ORCID 0000-0003-0020-7389

Funding

National Research Foundation of Korea NRF-2014R1A6A3A04054307National Research Foundation of Korea NRF-2017R1A5A2015061
6 · The paper itself

Abstract

Specific kinds of interleukin (IL) receptors are known to mediate lymphocyte proliferation and survival. However, recent reports have suggested that the high expression of IL4Rα and IL13Rα1 in tumor tissue might be associated with tumorigenesis in several kinds of tumor. We found that a significant association between mRNA level of IL4Rα or IL13Rα1 and the poor prognosis of renal cell carcinoma (RCC) from the public database (http://www.oncolnc.org/). Then, we evaluated the clinicopathological significance of the immunohistochemical expression of IL4Rα and IL13Rα1 in 199 clear cell RCC (CCRCC) patients. The individual and co-expression patterns of IL4Rα and IL13Rα1 were significantly associated with cancer-specific survival (CSS) and relapse-free survival (RFS) in univariate analysis. Multivariate analysis indicated IL4Rα-positivity and co-expression of IL4Rα and IL13Rα1 as the independent indicators of shorter CSS and RFS of CCRCC patients. For the in vitro evaluation of the oncogenic role of IL4Rα and IL13Rα1 in RCC, we knock-downed IL4Rα or IL13Rα1 and observed that the cell proliferation rate was decreased, and the apoptosis rate was increased in A498 and ACHN cells. Furthermore, we examined the possible role of Janus kinase 2 (JAK2), well-known down-stream tyrosine kinase under the heterodimeric receptor complex of IL4Rα and IL13Rα1. Interestingly, JAK2 interacted with Forkhead box O3 (FOXO3) to cause tyrosine-phosphorylation of FOXO3. Silencing IL4Rα or JAK2 in A498 and ACHN cells reduced the interaction between JAK2 and FOXO3. Moreover, pharmacological inhibition of JAK2 induced the nuclear localization of FOXO3, leading to increase apoptosis and decrease cell proliferation rate in A498 and ACHN cells. Taken together, these results suggest that IL4Rα and IL13Rα1 might be involved in the progression of RCC through JAK2/FOXO3 pathway, and their expression might be used as the novel prognostic factor and therapeutic target for RCC patients.

Indexed as

FOXO3IL13Rα1IL4RαJAK2renal cell carcinoma

Identifiers

PMID31540495
PMCPMC6770213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.